Latest Us Market News

Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.

Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.

EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.

Kelly Partners Group Holdings has secured conditional ASX approval to delist, clearing a regulatory milestone in its proposed move to Nasdaq. The plan still depends on shareholder approval and the US listing process, with no effective delisting date set.

Podium Minerals has improved flotation recovery at its Parks Reef PGM project to 67% while maintaining overall concentrator recovery near 80%, with a smaller targeted downstream circuit. The September quarter also delivered the full A$4 million underwritten raising and a proposed Australia-US processing partnership, though both the flowsheet and funding pathway still require further validation.

Stakk has won a minimum two-year agreement to provide AI-powered cheque-processing and fraud-mitigation technology to Step, the US fintech platform owned by MrBeast’s Beast Industries. The contract went live on signing, but its value remains undisclosed because revenue will depend on processing volumes.

Connexion Mobility has secured an exclusive supplier agreement with Hyundai Motor America to design, develop and manage a connected car-powered dealer lot platform across the United States. The strategic win adds a major OEM relationship, but its financial value and dealer uptake remain undisclosed.

Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.

First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.

Sunrise Energy Metals has signed a scheme deed to move its parent company from Australia to Delaware and make Nasdaq its primary listing, while retaining ASX exposure through CDIs. The proposed one-for-one exchange remains subject to shareholder, court, regulatory and listing approvals.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Resolution Minerals has turned Horse Heaven into the centre of its strategy, pairing broad gold drilling with high-grade antimony and tungsten test work. The expansion came with a sharply higher A$53.3 million FY2026 loss and a disclosed dependence on future funding.